This is not the most recent version of the article. View current version (18 APR 2016)

Intervention Review

You have free access to this content

Insulin and oral agents for managing cystic fibrosis-related diabetes

  1. Gary M Onady1,*,
  2. Adrienne Stolfi2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 26 JUL 2013

Assessed as up-to-date: 22 JUL 2013

DOI: 10.1002/14651858.CD004730.pub3


How to Cite

Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD004730. DOI: 10.1002/14651858.CD004730.pub3.

Author Information

  1. 1

    Wright State University, Boonshoft School of Medicine, Dayton, Ohio, USA

  2. 2

    Children's Medical Center, Department of Pediatrics, Dayton, Ohio, USA

*Gary M Onady, Boonshoft School of Medicine, Wright State University, Room 105, Medical Sciences Building, 3640 Colonel Glenn Highway, Dayton, Ohio, OH 45435, USA. gmonady@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 26 JUL 2013

SEARCH

This is not the most recent version of the article. View current version (18 APR 2016)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Grover 2008 {published and unpublished data}
Moran 2001 {published data only}
  • Milla CE, Phillips J, Moran A. Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD [abstract]. Pediatric Pulmonology 2001;32 (Suppl 22):335.
  • Moran A, Phillips J, Milla C. Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001;24(10):1706-10.
Moran 2009 {published and unpublished data}
  • Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009;32(10):1783-8.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Borowitz 2005 {published data only}
  • Borowitz D, Goss C, Limauro S, Murray F, Casey S, Cohen M. A dose-ranging study of efficacy of TheraCLEC-Total for treatment of pancreatic insufficiency [abstract]. Pediatric Pulmonology 2005;40 (Suppl 28):348.
  • Borowitz D, Goss CH, Limauro S, Murray F, Casey S, Cohen M, et al. A phase 2 study of TheraCLEC-Total enzymes in CF patients with pancreatic insufficiency (PI) [abstract]. Pediatric Pulmonology 2005;40 (Suppl 28):142.
  • Borowitz D, Konstan MW, Goss C, Limauro SE, Murray FT. Enhanced coefficient of fat absorption using a novel pancreatic enzyme preparation, ALTU-135, with concomitant use of a proton pump inhibitor [abstract]. Journal of Cystic Fibrosis 2006;5 Suppl:S56.
  • Borowitz D, Konstan MW, Goss C, Limauro SE, Murray FT, Casey S, et al. Treatment with ALTU-135 results in a positive inverse relationship between coefficient of fat absorption with stool weight in subjects with cystic fibrosis-related pancreatic insufficiency [abstract]. Journal of Cystic Fibrosis 2006;5 Suppl:S56.
  • Murray FT, Borowitz D, Konstan MW, Limauro SE, Goss C. Changes in coefficients of fat and nitrogen absorption in subjects with cystic fibrosis, pancreatic insufficiency, and cystic fibrosis-related diabetes mellitus receiving a novel pancreatic enzyme product, ALTU-135 [abstract]. Pediatric Pulmonology 2006;41 (Suppl 29):386.
Chernoff 2002 {published data only}
  • Chernoff RG, Ireys HT, DeVet KA, Kim YJ. A randomized, controlled trial of a community-based support program for families of children with chronic illness: pediatric outcomes. Archives of Pediatrics and Adolescent Medicine 2002;156(6):533-9.
  • Ireys HT, Chernoff R, DeVet KA, Kim Y. Maternal outcomes of a randomized controlled trial of a community-based support program for families of children with chronic illnesses. Archives of Pediatrics and Adolescent Medicine 2001;155(7):771-7.
Driscoll 2009 {published data only}
  • Driscoll KA, Johnson SB, Barker D, Quittner AL, Deeb LC, Geller DE, et al. Risk factors associated with depressive symptoms in caregivers of children with type 1 diabetes or cystic fibrosis. Journal of Pediatric Psychology 2010;35(8):814-22.
  • Driscoll KA, Johnson SB, Tang Y, Yang F, Deeb LC, Silverstein JH. Does blood glucose monitoring increase prior to clinic visits in children with type 1 diabetes?. Diabetes Care 2011;34(10):2170-3.
  • Driscoll KA, Killian M, Johnson SB, Silverstein JH, Deeb LC. Predictors of study completion and withdrawal in a randomized clinical trial of a pediatric diabetes adherence intervention. Contemporary Clinical Trials 2009;30(3):212-20.
Franzese 2005 {published data only}
  • Franzese A, Spagnuolo MI, Sepe A, Valerio G, Mozzillo E, Raia V. Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes?. Diabetes Care 2005;28(9):2333.
Hardin 2009 {published data only}
König 2005 {published data only}
Mahroukh 2005 {published data only}
  • Mahroukh R, Chapman K, Stewart C, Kelly E, Hanna A, Wilson DC, et al. Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. American Journal of Clinical Nutrition 2005;81(2):421-6.
Marshall 2005 {published data only}
Milla 2005 {published data only}
Minicucci 2008 {published data only}
  • Minicucci L. New diagnostic and therapeutic approaches in cystic fibrosis related diabetes (CFRD) [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 3):S6, Abstract no: R25.
  • Minicucci L, Casciaro R, De Alessandri A, Haupt M, Caso M, Lucidi V, et al. Efficacy of slow release insulin in patients with cystic fibrosis and glucide intolerance [abstract]. Journal of Cystic Fibrosis 2009;8 (Suppl 2):S82, Abstract no: 331.
Onady 2006 {published data only}
  • Onady GM, Langdon LJ. Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. BMC Endocrine Disorders 2006;6:4. [PUBMED: 16790062]
Peraldo 1998 {published data only}
Reali 2006 {published data only}
  • Reali MF, Festini F, Neri AS, Taccetti G, Repetto T, Chiarelli F, et al. Use of continuous subcutaneous insulin infusion in cystic fibrosis patients with cystic fibrosis-related diabetes awaiting transplantation. Journal of Cystic Fibrosis 2006;5(1):67-8.
Sulli 2007 {published data only}
  • Sulli N, Bertasi S, Zullo S, Shashaj B. Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: Three case reports. Journal of Cystic Fibrosis 2007;6(3):237-40.
Teeter 2004 {published data only}
  • Teeter JG, the Exubera ® Phase 3 Study Group, Pfizer Global Research and Development GCU. One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy [abstract]. European Respiratory Journal 2004;24(Suppl 48):P3773.
Ward 1999 {published data only}
  • Ward SA, Tomezsko JL, Holsclaw DS, Paolone AM. Energy expenditure and substrate utilization in adults with cystic fibrosis and diabetes mellitus. American Journal of Clinical Nutrition 1999;69(5):913-9.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
ADA 2004
  • American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27:S15-35.
Adler 2011
Culler 1994
  • Culler FL, McKean LP, Buchanan CN, Caplan DB, Meacham LR. Glipizide treatment of patients with cystic fibrosis and impaired glucose tolerance. Journal of Pediatric Gastroenterology and Nutrition 1994;18(3):375-8.
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, A Vail. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Finkelstein 1988
Hardin 1997
Higgins 2003
Higgins 2011
  • Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
Landers 1997
  • Landers A, Mathalone B, Byi KM, Hodson ME. Diabetic retinopathy in patients with cystic fibrosis related diabetes (CFRD) [abstract]. Pediatric Pulmonology 1997;24 (Suppl 14):306.
Lanng 1994
Moran 1991
Moran 2010
  • Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33(12):2697-708.
Quittner 2009
  • Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
Rosenecker 2001
Schwarzenberg 2007

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Onady 2005